Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept pharmacodynamic study of OV329 in photosensitive epilepsy
MOH_2026-08-03_016967Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of OV329 in photosensitive epilepsy (PSE) (3 cohorts), sponsored by Ovid Therapeutics. Primary endpoint: Pharmacodynamic effect on IPS-induced generalized PPR after single and repeated oral OV329 dosing. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
OV329
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on MOH_2026-08-03_016967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-03_016967.